CJC-1295 DAC

CJC-1295 DAC is a 30-amino-acid GHRH analog developed by ConjuChem Biotechnologies in the early 2000s as part of a program to create longer-acting versions of naturally occurring peptide hormones. The compound belongs to the same pharmacological family as native GHRH, a 44-amino-acid hypothalamic hormone that triggers growth hormone (GH) release from the anterior pituitary. Natural GHRH has a plasma half-life of only a few minutes, making it impractical as a therapeutic agent without continuous infusion. CJC-1295 DAC was designed to solve this problem through the proprietary Drug Affinity Complex technology, which incorporates a maleimidoproprionic acid (MPA) reactive group that forms a covalent bond with the cysteine-34 position on circulating serum albumin. This albumin-binding dramatically extends the peptide's half-life to an estimated six to eight days in humans.

Researchers study CJC-1295 DAC primarily because of its ability to produce sustained, dose-dependent increases in plasma GH and insulin-like growth factor 1 (IGF-1) levels. IGF-1 is the primary downstream mediator of many growth hormone actions, including protein synthesis, fat metabolism, and tissue repair. The compound's prolonged activity profile makes it a useful research tool for studying the biological effects of chronic, low-grade GH elevation, as opposed to the short, sharp GH pulses produced by standard GHRH or secretagogues.

Several structural features distinguish CJC-1295 DAC from both native GHRH and simpler synthetic analogs. Key substitutions include a D-Ala at position 2, which prevents cleavage by dipeptidyl peptidase IV (DPP-IV), an enzyme that rapidly degrades the native hormone. Additional modifications improve receptor binding affinity and overall molecular stability. These features, combined with the DAC technology, make CJC-1295 DAC one of the most pharmacokinetically extended GHRH analogs studied to date. Early human trials published around 2006 demonstrated that single doses could elevate mean GH levels for more than six days, an unprecedented duration for a peptide in this class. Despite this pharmacological interest, development as a formal therapeutic appears to have stalled, and the compound has not advanced beyond early clinical trials.

CJC-1295 DAC exerts its primary effect by binding to and activating the growth hormone-releasing hormone receptor (GHRH-R), a G protein-coupled receptor (GPCR) expressed on somatotroph cells in the anterior pituitary gland. Upon receptor binding, GHRH-R couples to the stimulatory G protein (Gs), activating adenylate cyclase and increasing intracellular cyclic adenosine monophosphate (cAMP) concentrations. Elevated cAMP activates protein kinase A (PKA), which phosphorylates downstream targets that promote both the synthesis and pulsatile release of growth hormone into systemic circulation.

The key pharmacokinetic innovation in CJC-1295 DAC is the Drug Affinity Complex modification at the lysine residue at position 30, where a maleimidoproprionic acid (MPA) side chain is conjugated. Following administration, the MPA group reacts spontaneously and covalently with the free thiol group on cysteine-34 of serum albumin. Because albumin has a natural half-life of approximately 19 days and is not filtered by the kidney, this binding event effectively 'hitchhikes' the peptide through the bloodstream for days rather than minutes. The albumin-bound peptide is protected from proteolytic degradation and renal clearance, explaining the observed plasma half-life of roughly six to eight days in humans.

An important structural modification that amplifies this durability is the substitution of D-alanine at position 2 of the peptide sequence. Native GHRH is rapidly inactivated by dipeptidyl peptidase IV (DPP-IV), which cleaves the His-Ala bond at the N-terminus. The D-Ala substitution makes this bond sterically inaccessible to DPP-IV, significantly extending the intrinsic stability of the peptide before albumin binding even occurs.

Downstream of GH secretion, the primary biological signal is mediated through IGF-1. GH released from the pituitary travels to the liver and other tissues, where it binds the GH receptor and stimulates hepatic IGF-1 synthesis and secretion. IGF-1 then activates the phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen-activated protein kinase (MAPK) pathways, promoting cell growth, protein synthesis, and lipolysis. CJC-1295 DAC research is therefore also a model for studying chronic IGF-1 pathway activation.

The published clinical research on CJC-1295 DAC is limited primarily to one key human study and a small number of supporting pharmacokinetic investigations, with no completed large-scale efficacy trials. The foundational human data comes from a 2006 study published in the Journal of Clinical Endocrinology and Metabolism by Jetté and colleagues, which evaluated the pharmacokinetics and pharmacodynamics of CJC-1295 DAC in 21 healthy adult subjects across multiple dose cohorts. The study found that single subcutaneous injections produced dose-dependent increases in mean 24-hour GH concentrations that persisted for 6 or more days, and dose-dependent increases in IGF-1 that were sustained for up to 14 days. At doses of 30 to 60 micrograms per kilogram, mean GH levels increased by two- to threefold over baseline. The study concluded that CJC-1295 DAC achieves pharmacological effects consistent with a weekly or biweekly dosing schedule, which was considered a notable achievement for a peptide-based compound at the time.

Multiple-dose data from the same research group suggested that repeated administration could maintain IGF-1 elevations within a range similar to that seen in younger, healthy adults. However, this multiple-dose investigation involved a small cohort, and no published placebo-controlled trials with clinical outcome endpoints have been conducted.

Animal model research, primarily in rodents and non-human primates conducted during the ConjuChem development program, confirmed GHRH-receptor agonism and demonstrated dose-dependent elevations in serum GH and IGF-1 consistent with the human pharmacokinetic findings. Rodent studies also reported increases in lean body mass and reductions in fat mass with sustained administration, though the applicability of these findings to humans has not been clinically tested in controlled trials.

A notable gap in the literature is the near-complete absence of published data on hard clinical outcomes such as muscle mass, bone density, body composition, or metabolic markers in human subjects. The research that exists is almost entirely pharmacokinetic and pharmacodynamic in nature. No published studies have examined long-term use, safety in special populations, or efficacy against any defined clinical endpoint in a randomized controlled trial. The compound did not progress through the typical phases of clinical development, and ConjuChem's development program was discontinued, meaning independent replication of existing findings in peer-reviewed literature is absent. Researchers interested in GHRH analog pharmacology have largely continued this work with related compounds, while CJC-1295 DAC itself has accumulated minimal new primary research after 2006.

The only published human dose-finding study, Jetté et al. 2006 in the Journal of Clinical Endocrinology and Metabolism, tested single subcutaneous doses ranging from 30 to 120 micrograms per kilogram of body weight across healthy adult cohorts. The 30 and 60 mcg/kg doses produced the most favorable GH and IGF-1 responses relative to tolerability. A separate multiple-dose cohort received repeated doses, but specific intervals and confirmed cumulative doses were not fully disclosed in the public publication. No subsequent completed human trial has established a therapeutic or optimized dose for CJC-1295 DAC.

The safety profile of CJC-1295 DAC is poorly characterized by the standards of modern clinical pharmacology. The available human data comes exclusively from the 2006 Jetté et al. study, which was a short-duration, small-sample pharmacokinetic investigation in healthy adults. Within that study, CJC-1295 DAC was generally described as well-tolerated at doses up to 60 mcg/kg subcutaneously. The most commonly reported adverse effects were transient injection-site reactions such as redness, swelling, and discomfort. Some subjects reported flushing, which is consistent with the vasodilatory effects known to accompany rapid GH release. These reactions were described as mild and self-limiting.

Theoretical safety concerns follow logically from the compound's mechanism. Any agent that chronically elevates GH and IGF-1 above physiological norms carries the theoretical risks associated with prolonged GH excess. In clinical endocrinology, pathological GH hypersecretion, as seen in acromegaly, is associated with insulin resistance, fluid retention (edema), carpal tunnel syndrome, joint pain, and, over very long timeframes, increased risk of certain malignancies. Whether the modest, sustained GH elevations produced by CJC-1295 DAC translate to these risks in healthy individuals at research-relevant doses has not been studied.

The extended half-life of CJC-1295 DAC, while pharmacologically useful, also presents a distinct safety consideration: adverse effects, if they occur, cannot be quickly reversed by stopping administration. The albumin-bound peptide will remain pharmacologically active for days after a dose regardless of the subject's clinical status.

No published long-term toxicology studies in animals or humans are available in the peer-reviewed literature. The compound's effects in people with pre-existing conditions, including insulin resistance, active or prior malignancy, or pituitary disease, are entirely unknown. Given the absence of regulatory approval and the very limited clinical trial data, the complete safety profile of CJC-1295 DAC must be considered unknown.

CJC-1295 DAC currently occupies a research-only position with no active regulatory development pathway. The compound was investigated by ConjuChem Biotechnologies in the mid-2000s and reached Phase I and early Phase II-equivalent human studies, but development appears to have been discontinued. No active registered clinical trials featuring CJC-1295 DAC are visible in major trial registries as of this writing.

Academic interest in GHRH analog pharmacology continues, though later-generation compounds and alternative secretagogues have attracted more research attention. The fundamental pharmacokinetic findings from the 2006 human study are cited in endocrinology and pharmacology literature as a demonstration of the albumin-binding DAC platform technology, even when the primary focus is on different compounds.

Key unresolved questions include whether chronic IGF-1 elevation from this compound produces meaningful changes in body composition or metabolic health in humans, and what the safety implications of long-term use are. No independent academic institution appears to have taken up active clinical investigation of CJC-1295 DAC specifically.